While there are many different things that could disrupt the flow of the supply chain, the world witnessed first hand, the impact the COVID-19 pandemic had on the global supply chain. The pandemic also altered access to an available labor pool for the 3PL provider. The ability to flex labor across all areas of the business, have helped to alleviate the shortage and maintain the level of service our customers have come to expect from us. Read the full article…
Serialization is here to stay. So how can you turn your gold mine of serialization data into the backbone of your digital transformation? Read the full article…
COVID-19 is doing more than changing the way we do business — it’s pulling the curtains back on pharmaceutical sourcing strategies and revealing their complexities. Read the full article…
Pharma and medical device buyers’ heavy reliance on global sourcing lowers costs but has created supply problems during the coronavirus pandemic. Read the full article…
This article shares insights on what we can expect to see in 2020 as the pharma supply chain industry continues to expand its digital transformation. Read the full article…
With US employment rates at their lowest in decades, combined with a variety of other factors, are testing traditional hiring methods. Now, the pharma industry is having to adopt new tactics for acquiring top talent. Read the full article…
Here are the steps that life science and healthcare companies are taking to embrace digital transformation. Read the full article…
MD Logistics, an Indiana based 3PL firm headquartered in Plainfield, announced the addition of a fourth facility, creating up to 50 new Hoosier jobs by the end of 2023. Read the full article…
As we start another year, we look back on the amazing year 2018 was, and forward in excited anticipation for what challenges and opportunities 2019 will bring our way. Read the full article…
Public criticism and scrutiny from lawmakers will likely remain, keeping biotech and pharma under pressure. At the same time, a cooperative FDA and scientific advances in oncology, cell and gene therapy should continue to serve as a tailwind, generating new approvals and investor optimism. Digital opportunities, including in artificial intelligence, have also proved attractive to drugmakers, spurring changes among executive teams. Here are seven trends to watch as 2019 unfolds… Read the full article…
